{{Rsnum
|rsid=1054191
|Gene=NR1I2
|Chromosome=3
|position=119818050
|Orientation=plus
|GMAF=0.1171
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(A;A)
|geno2=(A;G)
|geno3=(G;G)
|Gene_s=NR1I2
}}{{ population diversity
| geno1=(A;A)
| geno2=(A;G)
| geno3=(G;G)
| CEU | 2.7 | 35.4 | 61.9
| HCB | 0.0 | 0.0 | 100.0
| JPT | 0.0 | 0.0 | 100.0
| YRI | 2.7 | 17.0 | 80.3
| ASW | 3.5 | 28.1 | 68.4
| CHB | 0.0 | 0.0 | 100.0
| CHD | 0.0 | 0.0 | 0.0
| GIH | 0.0 | 14.9 | 85.1
| LWK | 4.5 | 33.6 | 61.8
| MEX | 1.7 | 22.4 | 75.9
| MKK | 0.6 | 17.3 | 82.1
| TSI | 2.9 | 39.2 | 57.8
| HapMapRevision=28
}}{{PMID Auto
|PMID=19940802
|Title=The nuclear receptor PXR gene variants are associated with liver injury in nonalcoholic fatty liver disease
}}

{{PMID Auto
|PMID=19739075
|Title=Polymorphisms in genes of the steroid receptor superfamily modify postmenopausal breast cancer risk associated with menopausal hormone therapy
}}
{{PMID Auto
|PMID=19958310
|Title=The influence of common gene variants of the xenobiotic receptor (PXR) in genetic susceptibility to intrahepatic cholestasis of pregnancy
}}

{{PMID Auto
|PMID=24926315
|Title=Genetic variation in the 3'-UTR of CYP1A2, CYP2B6, CYP2D6, CYP3A4, NR1I2, and UGT2B7: potential effects on regulation by microRNA and pharmacogenomics relevance
}}
{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | FTDNA2}}
{{on chip | HumanOmni1Quad}}
{{on chip | Illumina Human 1M}}